

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,

Karachi

No.2/2/2003-F.Sec.

Dated: 03.03.2007

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 9-12-2006 TO BE PUBLISHED ON 05-03-2007 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1594/2006	<u>04-12-2006</u> Otsuka Pharamacutical Co. Ltd. Japan. (Priority 05-12-2005 Japan)	“Medicinal drug”
1595/2006	Brasilata S/A Embalagens Metalicas Brazil. (Priority 06-12-2005 Brazi)	“Can closure arrangement”
1596/2006	Neuro Search A/S. Denmark. (Priority 05-12-2005 Danish)	“Novel compounds”
1597/2006	Graduate Group SDN BHD. Malaysia.	“A set of parts and an article for cleaning assembled therefrom”
1598/2006	Novartis AG. Switzerland. (Priority 08-12-2005 US)	“Organic compounds”
1599/2006	Novartis AG. Switzerland. (Priority 08-12-2005 US)	“Organic compounds”
1600/2006	<u>05-12-2006</u> Seldon Laboratories, LLC. USA. (Priority 05-12-2005 USA)	“Method of generating energetic particles using nanotubes and articles thereof”
1601/2006	N.V.Organon. Netherlands. (Priority 08-12-2005 EP)	“Isoquinoline derivatives”
1602/2006	Syngenta Limited. United Kingdom. (Priority 21-12-2005 UK)	“Novel Herbicides”
1603/2006	AstraZeneca AB. Sweden. (Priority 15-12-2005 US)	“Combinations”

1604/2006	AstraZeneca AB. Sweden. (Priority 15-12-2005 Sweden)	“New compounds for the treatment of cardiac arrhythmias”
1605/2006	1.Amgen Fremont Inc U.S.A. 2.AstraZeneca AB, Sweden. (Priority 13-12-2005 US)	“Binding proteins specific for insulin-like growth factors and uses thereof”
1606/2006	Janssen Pharmaceutical N.V. Belgium. (Priority 21-12-2005 US)	“Triazolopyridazines as kinase modulators”
1607/2006	Aventis Pharmaceutica Inc. USA. (Priority 08-12-2005 US)	“Use of a CBI antagonist for treating side effects and negative symptoms of schizophrenia”
1608/2006	Novartis AG. Switzerland. (Priority 09-12-2005 GB)	“Organic Compounds”
1609/2006	Novartis AG. Switzerland. (Priority 09-12-2005 GB)	“Organic Compounds”
	<u>06-12-2006</u>	
1610/2006	Otsuka Pharmaceutical Co. Ltd. Japan. (Priority 06-12-2005 Japan)	“Equal-containing fermented soybean hypocotyls and method of producing the same”
1611/2006	Wyeth. USA. (Priority 07-12-2005 USA)	“Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate”
1612/2006	Wyeth. USA. (Priority 07-12-2005 USA)	“Process for the preparation of purified crystalline CCI-779”
1613/2006	Wyeth. USA. (Priority 07-12-2005 USA)	“Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry”
1614/2006	Honda Motor Co. Ltd.	“Twin clutch device”

	Japan. (Priority 28-12-2005 Japan)	
1615/2006	Glaxo Group Limited. Great Britain.	“Novel forms”
	<u>07-12-2006</u>	
1616/2006	Pfizer Products Inc. USA. (Priority 09-12-2005 USA)	“Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7H- pyrrolo[2,3-D] pyrimidine-5-carbonyl)-2-methoxy-pheny l]-3-(2,4-dichloro-phenyl)-urea”
1617/2006	AstraZeneca AB. Sweden. (Priority 12-12-2005 Sweden)	“Novel compounds”
	<u>08-12-2006</u>	
1618/2006	1. Tahera Khatoon. 2. Rashid Ali Siddiqui. P.C.S.I.R ,Karachi	“A process for the production of copper oxychloride”
1619/2006	Novartis AG. Switzerland. (Priority 03-04-2002 GB) Divisional	“A salt of an indolylmaleimide compound and a pharmaceutical composition comprising thereof”
	<u>09-12-2006</u>	
1620/2006	Telenor ASA. Norway. (Priority 12-12-2005 Norway)	“Method, subscriber identity module and system for providing mobile communication terminal location data”
1621/2006	Glaxo Group Limited. Great Britain. (Priority 12-12-2005 GB)	“Medicament dispenser”
1622/2006	Glaxo Group Limited. Great Britain. (Priority 12-12-2005 GB)	“Manifold for use in medicament dispenser”
1623/2006	Sanofi-Aventis U.S. LLC. USA. (Priority 14-12-2005 US)	“Fexofenadine suspension formulation”
1624/2006	1. AstraZeneca AB.	“Novel hydrogen sulfate salt”

Sweden.
2. Array Biopharma Inc.
USA.
(Priority 21-12-2005 USA)

1625/2006	1. Institut Francais DU petrole France. 2. ENI S.p.A. Italy. (Priority 20-12-2005 France)	“Secondary filtration device applicable to a three-phase process”
1626/2006	Honda Motor Co. Ltd. Japan. (Priority 31-01-2006 Japan)	“Internal combustion engine for vehicle”
1627/2006	Bayer CropScience AG. Germany. (Priority 13-12-2005 Germany)	“Insecticidal compositions with improved activity”
1628/2006	Bayer CropScience AG. Germany. (Priority 13-12-2005 Germany)	“Insecticidal compositions having improved activity”

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139200	Wyeth, U.S.A.	896/2004
139201	Smithkline Beecham Corporation, U.S.A.	901/2004
139202	Freedom Health, LLC, U.S.A.	902/2004
139203	Almirall Pridesfarna, S.A., Spain	903/2004

139204	BP Corporation North America Inc., U.S.A.	911/2004
139205	The University of Queensland. Australia	914/2004
139206	Solvay (Societe Anonyme), Belgium	916/2004
139207	The University of Queensland, Australia	933/2006
139208	The University of Queensland, Australia	934/2006
139209	The University of Queensland, Australia	935/2006
139210	The University of Queensland, Australia	936/2006

(Mrs. Yasmeen Abbasi)
Controller of Patents & Designs
Tel: 9215488